PL397563A1 - Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof - Google Patents

Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof

Info

Publication number
PL397563A1
PL397563A1 PL397563A PL39756311A PL397563A1 PL 397563 A1 PL397563 A1 PL 397563A1 PL 397563 A PL397563 A PL 397563A PL 39756311 A PL39756311 A PL 39756311A PL 397563 A1 PL397563 A1 PL 397563A1
Authority
PL
Poland
Prior art keywords
pharmaceutical form
tablet
angiotensin
losartan
potassium
Prior art date
Application number
PL397563A
Other languages
Polish (pl)
Other versions
PL218490B1 (en
Inventor
Andrzej Ostrowicz
Original Assignee
Biofarm Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofarm Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Biofarm Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL397563A priority Critical patent/PL218490B1/en
Publication of PL397563A1 publication Critical patent/PL397563A1/en
Publication of PL218490B1 publication Critical patent/PL218490B1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Postac farmaceutyczna zawierajaca terapeutycznie skuteczna ilosc antagonisty receptorów typu AT1 angiotensyny II, którym jest sól potasowa losartanu, charakteryzuje sie tym, ze stanowi ja tabletka powlekana zawierajaca substancje czynna - losartan potasu, naniesiony na nosnik, którym jest laktoza jednowodna, w ilosci od 10% do 27% wagowych w stosunku do calkowitej masy tabletki, oraz stearylofumaran sodu w ilosci od 2% do 3% wagowych w stosunku do calkowitej masy tabletki jako substancje poslizgowa i inne substancje pomocnicze wybrane sposród substancji wiazacych oraz substancji dezintegrujacych. Przedmiotem wynalazku jest takze sposób wytwarzania okreslonej powyzej postaci farmaceutycznej, który polega na tym, ze losartan potasu nanosi sie na ziarna jednowodnej laktozy w procesie granulacji fluidyzacyjnej, wytworzony granulat miesza sie z substancja wiazaca, substancja dezintegrujaca oraz substancja poslizgowa, która stanowi stearylofumaran sodu. Nastepnie wytworzona mieszanine tabletkuje sie, a rdzenie tabletek powleka.The pharmaceutical form containing a therapeutically effective amount of the angiotensin II type AT1 receptor antagonist, which is losartan potassium, is characterized by being a film-coated tablet containing the active substance - potassium losartan, applied to a carrier which is lactose monohydrate, in an amount of 10% to 27% by weight relative to the total weight of the tablet, and sodium stearyl fumarate in an amount of 2% to 3% by weight relative to the total weight of the tablet as a lubricant and other excipients selected from binders and disintegrants. The invention also relates to a process for the preparation of the above-described pharmaceutical form, which consists in the fact that potassium losartan is applied to grains of lactose monohydrate in a fluidization granulation process, the resulting granules are mixed with a binder, disintegrant and glidant, which is sodium stearyl fumarate. The resulting mixture is then tableted and the tablet cores coated.

PL397563A 2011-12-27 2011-12-27 Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof PL218490B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL397563A PL218490B1 (en) 2011-12-27 2011-12-27 Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL397563A PL218490B1 (en) 2011-12-27 2011-12-27 Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof

Publications (2)

Publication Number Publication Date
PL397563A1 true PL397563A1 (en) 2013-07-08
PL218490B1 PL218490B1 (en) 2014-12-31

Family

ID=48748711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL397563A PL218490B1 (en) 2011-12-27 2011-12-27 Pharmaceutical form comprising a therapeutically effective amount of an angiotensin II receptors AT1 - potassium losartan and a process for production thereof

Country Status (1)

Country Link
PL (1) PL218490B1 (en)

Also Published As

Publication number Publication date
PL218490B1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX2013008431A (en) Mineralocorticoid receptor antagonists.
RS54329B1 (en) Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
PH12014502341A1 (en) Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
NZ703124A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
UA106057C2 (en) Normal;heading 1;heading 2;heading 3;PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUND, THEIR PHARMACEUTICAL COMPOSITION CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR
UA115320C2 (en) Kinase inhibitors
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MX336051B (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
MX2013012588A (en) Kinase inhibitors.
MY153712A (en) Preparation of controlled release skeletal muscle relaxant dosage forms
NZ628993A (en) Pharmaceutical formulations comprising ccr3 antagonists
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
MX344846B (en) Combination of active loaded granules with additional actives.
NZ703152A (en) Dosing regimen for janus kinase (jak) inhibitors
MX2013014577A (en) Heteroaryl compounds as 5-ht4 receptor ligands.
PH12014501408A1 (en) Immediate release multi unit pellet system
AR100977A1 (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION
MY161236A (en) (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
MX339858B (en) Novel compounds as histamine h3 receptor ligands.
MX345544B (en) Triazole derivatives as ligands for gaba receptors.
MX2014002395A (en) Novel rock kinase inhibitors.
WO2010136035A3 (en) Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof